Select the drug indication to add to your list


Only 4 drugs may be compared at once

Generic Name and Formulations:

Pimavanserin 17mg; tabs.

Select therapeutic use:

Indications for NUPLAZID:

Treatment of hallucinations and delusions associated with Parkinson's disease (PD) psychosis.


34mg (taken as two 17mg tablets) once daily ­without titration. Concomitant strong CYP3A4 inhibitors: 17mg once daily. Concomitant strong CYP3A4 inducers: monitor and dose increase may be needed.


Not established.


Elderly with dementia-related psychosis: increased risk of death. Not for treating patients with dementia-related psychosis unrelated to the hallucinations/delusions associated with PD psychosis. Avoid in patients with known or congenital QT prolongation, history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia, or hypomagnesemia. Hepatic or severe renal impairment (CrCl <30mL/min): not recommended. Pregnancy. Nursing mothers.


Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, clarithromycin, indinavir); reduce dose by ½. Antagonized by strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort); monitor for reduced efficacy. Avoid concomitant use with other drugs known to prolong QT interval including Class 1A (eg, quinidine, procainamide, disopyramide) or Class 3 antiarrhythmics (eg, amiodarone, sotalol), certain antipsychotics (eg, ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (eg, gatifloxacin, moxifloxacin).

Pharmacological Class:

Atypical antipsychotic.

Adverse Reactions:

Peripheral edema, confusional state, nausea, hallucination, constipation, gait disturbance.

Generic Availability:


How Supplied:


NUPLAZID 17mg tablets (Qty:60)

appx. price $2843.00